首页> 美国卫生研究院文献>Radiation Oncology (London England) >Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy
【2h】

Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy

机译:新的第8期TNM分期系统在非小细胞肺癌中的应用:治愈性同时放化疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe eighth tumor, node, metastasis (TNM) staging system (8-TNM) for non-small cell lung cancer (NSCLC) was newly released in 2015. This system had limitation because most patients included in the analysis were treated with surgery. Therefore, it might be difficult to reflect prognosis of patients treated with curative concurrent chemoradiotherapy (CCRT). Purpose of this study was to investigate clinical impact of the newly published 8-TNM compared to the current seventh TNM staging system (7-TNM) for locally advanced NSCLC patients treated with CCRT.
机译:背景资料非小细胞肺癌(NSCLC)的第八个肿瘤,淋巴结转移(TNM)分期系统(8-TNM)于2015年新发布。该系统有局限性,因为分析中包括的大多数患者均接受了手术治疗。因此,可能难以反映出同时进行根治性放化疗的患者的预后。这项研究的目的是调查与当前第七种TNM分期系统(7-TNM)相比,新发布的8-TNM对接受CCRT治疗的局部晚期NSCLC患者的临床影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号